TITLE

Long-term safety, efficacy, and patient acceptability of teriparatide in the management of glucocorticoid-induced osteoporosis

AUTHOR(S)
Dore, Robin K.
PUB. DATE
May 2013
SOURCE
Patient Preference & Adherence;2013, Vol. 7, p435
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Glucocorticoids are commonly prescribed medications to treat multiple diseases across many medical specialties. One of the most common yet largely unappreciated side effect of glucocorticoid use is increased risk of fracture. Many different therapies are indicated to prevent and treat this condition; many guidelines exist that suggest appropriate use of both glucocorticoids and the medications approved to prevent this common side effect of glucocorticoid therapy. Nevertheless, 30%-50% of patients on long-term glucocorticoid therapy sustain a fracture. Teriparatide, recombinant human parathyroid hormone (1-34), is a daily self-injectable therapy for 24 months approved for use in patients taking long-term glucocorticoids. Teriparatide has been shown to increase bone mineral density and reduce vertebral fracture risk in glucocorticoid-treated patients. Glucocorticoids have many adverse effects on bone that teriparatide has been shown to prevent or negate. Given the fact that preventive therapy for glucocorticoid-induced osteoporosis is often not prescribed, one wonders whether a daily self-injectable therapy for this condition would be prescribed by physicians and accepted by patients. This article reviews the epidemiology, pathophysiology, treatment, guidelines, and persistence data (when available) for patients with glucocorticoid-induced osteoporosis treated with teriparatide.
ACCESSION #
87991742

 

Related Articles

  • Daily and Cyclic Parathyroid Hormone in Women Receiving Alendronate. Cosman, Felicia; Nieves, Jeri; Zion, Marsha; Woelfert, Lillian; Luckey, Marjorie; Lindsay, Robert // New England Journal of Medicine;8/11/2005, Vol. 353 Issue 6, p566 

    Background: We evaluated whether patients with osteoporosis treated with long-term alendronate have a response to parathyroid hormone treatment and whether short, three-month cycles of parathyroid hormone therapy could be as effective as daily administration. Methods: We randomly assigned 126...

  • Alternate Treatment for Osteoporosis.  // Clinical Oncology Alert;Apr2007, Vol. 23 Issue 4, p2 

    The article discusses research being done on a recombinant human parathyroid hormone, a bone forming agent which can be an alternative treatment for osteoporosis. It references a study published in the 2006 issue of "Annals of Internal Medicine." The study concludes that parathyroid hormone...

  • Alternate Treatment for Osteoporosis.  // Infectious Disease Alert;Apr2007, Vol. 26 Issue 7, p2 

    This article discusses findings of a study which focused on recombinant human parathyroid hormone (PTH) as an alternative treatment for osteoporosis. Antiresorptive agents, like bisphosphonates, alendronate and risedronate, are the standard therapy for osteoporosis. PTH is a bone-forming agent,...

  • Parathyroid Hormone versus Bisphosphonate Treatment on Bone Mineral Density in Osteoporosis Therapy: A Meta-Analysis of Randomized Controlled Trials. Ongxiang Shen; Xuetao Xie; Yan Su; Congfeng Luo; Changqing Zhang; Bingfang Zeng // PLoS Clinical Trials;Oct2011, Vol. 8 Issue 10, Special section p1 

    Background: Bisphosphonates and parathyroid hormone (PTH) represent the antiresorptive and anabolic classes of drugs for osteoporosis treatment. Bone mineral density (BMD) is an essential parameter for the evaluation of anti-osteoporotic drugs. The aim of this study was to evaluate the effects...

  • Influence of Daily Regimen Calcium and Vitamin D Supplementation on Parathyroid Hormone Secretion. Reginster, J.-Y.; Zegels, B.; Lejeune, E.; Micheletti, M. C.; Kvsaz, A.; Seidel, L.; Sarlet, N. // Calcified Tissue International;Feb2002, Vol. 70 Issue 2, p78 

    Calcium and vitamin D supplementation has been shown to reduce secondary hyperparathyroidism and play a role in the management of senile osteoporosis. In order to define the optimal regimen of calcium and vitamin D supplementation to produce the maximal inhibition of parathyroid hormone...

  • Intermittently administered parathyroid hormone 1—34 reverses bone loss and structural impairment in orchiectomized adult rats. Gabet, Yankel; Kohavi, David; Müller, Ralph; Chorev, Michael; Bab, Itai // Osteoporosis International;Nov2005, Vol. 16 Issue 11, p1436 

    Male osteoporosis is emerging as a central theme in bone research. As in females, hypogonadism appears as a principal risk factor in men that leads to bone loss and increased fracture incidence. Intermittently administered parathyroid hormone (PTH) reverses bone loss in sex hormone-deprived...

  • Recombinant Full-Length Parathyroid Hormone (1-84): A Viewpoint by Dieter Felsenberg. Felsenberg, Dieter // Drugs;2006, Vol. 66 Issue 18, p2382 

    â–´ The fentanyl buccal tablet (FBT) is a new formulation of fentanyl that uses an effervescent drug delivery system to enhance penetration across the buccal mucosa for the treatment of breakthrough pain in opioid-tolerant patients with cancer.â–´ Fentanyl is rapidly absorbed from FBT...

  • Osteoporosis.  // Current Medical Literature: Rheumatology;2006, Vol. 25 Issue 3, p80 

    The article presents several published studies on osteoporosis. One of the studies provide an economic evaluation of parathyroid hormone in the treatment of osteoporosis in postmenopausal women. Another study found that the most effective approach to parathyroid hormone for osteoporosis is to...

  • IOQPTH.  // Taber's Cyclopedic Medical Dictionary (2009);2009, Issue 21, p1230 

    A definition of the acronym "IOQPTH" which refers to intraoperative quick assay of intact parathyroid hormone is presented.

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics